Lacosamide Tablet, Film Coated
Product Images NDC 70518-4561

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 70518-4561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Lacosamide 100mg 70518 4561 00)

Lacosamide 100 mg tablet film coated, controlled substance Schedule C-V, 30 tablets per box. The label includes the product NDC 70518-4561-00, repackaged by RemedyRepack Inc., Indiana, PA. It also states federal law restrictions on drug transfer and storage instructions, with manufacturer information from Ascend Labs.*

FDA Label Image

Remedy_label (Remedy Label)

Lacosamide 100 mg film-coated tablet label showing a single oral tablet quantity. The label includes the proprietary name, dosage strength, NDC number 70518-4561-01, and the labeler RemedyRepack Inc. It also features federal caution regarding drug transfer and storage instructions, along with manufacturer details for Ascend Labs, LLC.*

FDA Label Image

Laco-fig1.jpg (Laco Fig1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing placebo and various doses of Lacosamide in three separate studies. The vertical axis shows seizure reduction as median percent change from baseline, ranging from 0% to 45%. The chart demonstrates increased seizure reduction with higher Lacosamide doses (200 mg/day to 600 mg/day) compared to placebo across Studies 2, 3, and 4, with statistically significant differences marked by asterisks.*

FDA Label Image

Laco-fig2.jpg (Laco Fig2)

A graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4'. It shows responder rate (equal to or greater, representing improvement and worsening) on the vertical axis and percent of patients on the horizontal axis. Four lines represent placebo and Lacosamide dosages of 200 mg/day, 400 mg/day, and 600 mg/day, with corresponding sample sizes. The chart compares patient responder rates across these groups.*

FDA Label Image

Laco-fig3-a (Laco Fig3 A)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between Lacosamide and placebo groups. The graph includes risk numbers at various time points and statistical data including a p-value, hazard ratio (HR), and 95% confidence interval (CI). The Lacosamide group is represented by a dashed line, and the placebo group by a solid line.*

FDA Label Image

Laco-str (Laco Str)

Chemical structure of the active ingredient lacosamide, showing its molecular arrangement including functional groups and bonding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.